SCHEMBL5162575

SCHEMBL5162575

CN(C)c1ccc(NC(=O)[C@H](N)Cc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 2/20 0.56
ALDH1A1 P00352 3/20 0.54
NPC1 O15118 2/20 0.54
RAB9A P51151 2/20 0.54
MAPT P10636 2/20 0.54
ALOX15 P16050 1/20 0.54
NFKB1 P19838 1/20 0.54
MAPK1 P28482 1/20 0.54
NFKB2 Q00653 1/20 0.54
RELA Q04206 1/20 0.54
MCL1 Q07820 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
NOX1 Q9Y5S8 1/20 0.52
NPY1R P25929 1/20 0.51
NPY2R P49146 1/20 0.51
F7 P08709 1/20 0.51
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
HDAC8 Q9BY41 1/20 0.50
CIT O14578 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5162582 1.00 BACE1 (0.56) BACE1ALDH1A1NPC1RAB9AMAPT
SCHEMBL28279157 0.85 BACE1 (0.63) BACE1NPC1RAB9AKMT2AMEN1
SCHEMBL2312372 0.85 BACE1 (0.63) BACE1NPC1RAB9AKMT2AMEN1
SCHEMBL2312361 0.85 BACE1 (0.63) BACE1NPC1RAB9AKMT2AMEN1
SCHEMBL630340 0.84 NPC1 (0.60) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL631407 0.84 SMN1; SMN2 (0.45) BACE1ALDH1A1NPC1RAB9AMAPT
SCHEMBL9572030 0.84 ALDH1A1 (0.50) ALDH1A1NPC1RAB9AMAPTALOX15
SCHEMBL28085751 0.84 MAPK1 (0.63) BACE1ALDH1A1NPC1RAB9AMAPK1
SCHEMBL28085745 0.84 MAPK1 (0.63) BACE1ALDH1A1NPC1RAB9AMAPK1
SCHEMBL29002157 0.84 MAPK1 (0.63) BACE1ALDH1A1NPC1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1964955-A Small molecules for treatment of hypercholesterolemia and related diseases AVANIR PHARMACEUTICALS (US) 2007-05-16 CN disclosed
EP-1753733-A1 SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES Avanir Pharmaceuticals (US) 2007-02-21 EP disclosed
WO-2005123700-A1 SMALL MOLECULES FOR TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED DISEASES AVANIR PHARMACEUTICALS (US) 2005-12-29 WO disclosed
US-20050277690-A1 Small molecules for treatment of hypercholesterolemia and related diseases AVANIR PHARMACEUTICALS 2005-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050277690-A1 Small molecules for treatment of hypercholesterolemia and related diseases LDLR, NPC1L1, CETP BACE1 1226/4885ALDH1A1 4484/4885NPC1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.